Health insurance benefits for MSD Korea’s ‘Zepatier’ from this May

Published: 2017-04-27 16:04:18

Updated: 2017-04-27 16:04:18

‘Zepatier,’ a MSD Korea’s chronic hepatitis C treatment, will be applied for the health insurance system from the 1^st of May.

MSD Korea(CEO Avi BenShoshan) announced on the 25^th at a press conference that the health insurance benefits will be applied on ‘Zepatier(generic name: elbasvir/grazoprevir),’ its chronic hepatitis C drug, for chronic hepatitis C genotype 1/4 adult patients from 1 May 2...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.